Edaravone (Daiichi Sankyo)

Edaravone (Daiichi Sankyo) for sale – Buy Edaravone (Daiichi Sankyo) Online

What is edaravone for?

Edaravone is a radical scavenger used to treat patients with acute and acute ischaemic stroke^[1][2]. Edaravone is used also for the treatment of patients with ALS^[3,4].

How does edaravone work?

Free radicals such as hydroxyl radical (-OH) play a major causative role in the development of cerebral vascular disorder resulting from ischaemia.

During ischaemia or ischaemic reperfusion, the production of free radicals increases which leads to cell membrane injury and ultimately to cerebral dysfunction. By eliminating free radicals, it is effective to suppress cell membrane lipid peroxidation^[1][2].

Where has edaravone been approved?

Edaravone was approved by the PMDA (JAP) for the treatment of acute cerebral infarction.^[1][2]

The active ingredient edaravone is the main component of a drug produced by Mitsubishi Tanabe named Radicut in Japan and Radicava in USA. Under these names, edaravone is approved for the treatment of patients affected by ALS. This version of edaravone is a generic medicine, manufactured by Daiichi Sankyo. Please contact our support team to verify which form we can currently get for you. It may differ from the picture and manufacturer shown on this page.^[6][7][8].

Please be aware that any decision to use a prescription generic or brand name medicine should always be taken in consultation with a medical professional. The FDA has sent warning letters to drugmakers in India concerning the quality of their medicines.

How is edaravone taken?

Complete information about edaravone dosage and administration for the treatment of cerebral infarction can be found in our resources section^[1][2].

• 30 mg of edaravone administered intravenously over 30 minutes twice a day in the morning and the evening.
• Administration of this product should be initiated within 24 hours after the onset of the disease, and the duration of administration should be within 14 days.
• Consider terminating administration in a shorter period depending on symptoms.

Edaravone is the active ingredient of two other drugs, Radicut and Radicava, which are indicated for the treatment of ALS. The standard dosage of Radicut and Radicava for adult patients with ALS is^[3][4]:

• 60 mg of edaravone (2 vials/bags) administered intravenously over 60 minutes once a day.
• First cycle: daily dosing for 14 days followed by a 14-day drug-free period (28 vials/bags).
• Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (20 vials/bags).

Edaravone is supplied in two formats:

• Single-dose infusion bags containing 30 mg / 100 mL clear, colorless, sterile solution. The infusion bags are ready for use. No dilution is required^[2].
• Single-dose vials containing 30 mg / 20 mL clear, colorless, sterile solution. Before the infusion, it should be diluted with an appropriate volume of physiological saline^[1].

Warning: Administer carefully to patients with renal dysfunction and dehydration, infectious diseases, liver dysfunction, heart disease, advanced consciousness disorder and to elderly people^[1][2].

Note: Please consult with your treating doctor for personalised dosing.

References

1. Summary of Product Characteristics [PMDA]: Edaravone Pfizer (edaravone) – Injection [PDF]
       Pfizer, July 2015.2. Summary of Product Characteristics [PMDA]: Edaravone Pfizer (edaravone) – Injection Bag  [PDF]
       Pfizer, July 2015.

   3. Summary of Product Characteristics [PMDA]: Radicut (edaravone) [PDF]
   Mitsubishi Tanabe Pharma Corporation, June 2015.

   4. Summary of Product Characteristics [FDA]: Radicava (edaravone) [PDF]
       MT Pharma America Inc., May 2017.

   5. EMA. Public summary of opinion on orphan designation
       23/02/2015.

   6. Summary of Product Characteristics [FDA]: Radicava (edaravone) [PDF]
   MT Pharma America Inc., May 2017.

   7. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener.
   Abe K., et al.  2014 Dec; 15(7–8):610–7

   8. Yoshino H. and Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
   Amyotroph Lateral Scler. 2006 Dec.; 7(4):241–5.

For more information please visit our blog page “What is Radicut/Radicava?”

This content has been reviewed by a Medical Doctor.